1 **Associating antiretroviral therapy initiated before or during pregnancy with placenta**
2 **pathology in HIV infected women.**
3

4 Nadia M IKUMI, PhD[1†], Thokozile R MALABA, MPH[2†], Komala PILLAY, MD[3,4], Marta C COHEN,
5 MD[5,6], Hlengiwe P MADLALA, PhD[2], Mushi MATJILA, MD, PhD[7], Dilly ANUMBA, MD[8], Landon
6 MYER, MD, PhD[2], Marie-Louise NEWELL, PhD[9,10], and Clive M GRAY, PhD[1, 4*], for the PIMS
7 Study Group[9,10]
8

[1]Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University
of Cape Town, Cape Town, South Africa
[2]Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine,
University of Cape Town, Cape Town, South Africa
[3]Division of Anatomical Pathology, Department of Pathology, University of Cape Town, Cape
Town, South Africa
[4]National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa
[5]Department of Histopathology, Sheffield Children's NHS Foundation Trust , Sheffield, UK
[6]Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town South
Africa
[7]Department of Obstetrics and Gynaecology, University of Cape Town, Cape Town South
Africa
[8]Academic Unit of Reproductive and Developmental Medicine, University of Sheffield,
Sheffield, United Kingdom
[9]School of Human Development and Health, Faculty of Medicine, University of
Southampton, Southampton, United Kingdom
[10]School of Public Health, Faculty of Health Sciences, University of Witwatersrand,
Johannesburg, South Africa
28

29 **Conflict of interest statement**
30
31 The authors report no conflict of interest.
32

Funding Statement: The research reported in this publication was supported by the Eunice
Kennedy Shriver National Institute of Child Health & Human Development of the National
Institutes of Health under Award Number R01 HD080385 (PIMS Prematurity Immunology in
HIV-Infected Infants and their Infants Study); also in part by the National Institute for Health
Research (NIHR) (17/63/26) using UK Government aid to support global health research and
by the Academy of Medical Sciences networking grant. The views expressed in this
publication are those of the author(s) and not necessarily those of the NIHR or the UK
Department of Health and Social Care.
41

42 [†]Co-First Authors
43

*Corresponding Author
Clive M Gray, Division of Immunology, Institute of Infectious Disease and Molecular
Medicine, Falmouth Building, Faculty of Health Sciences, University of Cape Town, Anzio

Road, Observatory, Cape Town, South Africa, 7925; Tel: +27 21 406 6616; Email:
clive.gray@uct.ac.za

ABSTRACT
Background
Antiretroviral therapy (ART) is universally recommended for all HIV-infected pregnant
women to improve survival and to reduce mother-to-child HIV transmission. With
widespread use of ART in areas of high HIV prevalence, there is concern that prolonged *in-*
utero ART exposure may result in adverse birth outcomes, such as preterm delivery and low
birthweight infants. Underlying drivers of these effects may be found in the placenta.
56
57   **Objective**
58   We examined whole placentas from live births to seek an association between timing of ART
59   initiation and pregnancy outcome.
60
Study Design
This was a nested sub-study in a larger cohort of HIV-infected women recruited in a large
primary care antenatal clinic in Cape Town, South Africa. Whole placentas (n=130) were
collected at delivery and examined for histopathology from two ART groups. The *stable*
group (n=53) initiated ART prior to pregnancy and the *initiating* group (n=77) started ART at
a median of 15 weeks gestation. Adverse birth outcomes were defined by preterm delivery
(PTD; n=9), small-for-gestational age (SGA; n=12) and low birthweight (LBW; n=11) in the
two groups. Wilcoxon rank-sum and t-tests were used to measure differences in placental
histopathology by ART group. Binomial and univariate linear regression models, chi-squared
or Fisher's exact test were used to quantify associations between placenta histopathology
and maternal factors including ART timing and the association with pregnancy outcome.
72
Results
Women in the *stable* group were significantly older (median [IQR] 33 years [28 - 37] *vs* 28
[25 - 32]; p=0.003), had higher CD4 cell counts 455 cells/ml [381 - 602] *vs* 369.5 [251 -
534.5], p=0.04) and were less likely to be prehypertensive or hypertensive at first antenatal
care visit (p=0.03) than women in the *initiating* group. Overall, 119 (91%), women were on a
fixed dose regimen of Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV) and only 3 (2%;
all in the *stable* group) were on a protease inhibitor (PI)-based regimen with no difference
between the groups. Overall, nearly a third of placentas were small, although the fetal-
placenta weight ratio was in the normal range for most women. Meconium exposure and
chorioamnionitis was seen in 19% and 15% of placentas, respectively. Apart from maternal
vascular malperfusion (MVM) and decidual arteriopathy, histopathology obervations did not
differ significantly between stable and initiating groups. Placentas from the *stable* group
showed increased MVM (39.6% *vs* 19.4%, p=0.01) and decidual arteriopathy (11.3% *vs* 1.3%,
p=0.02), with a trend of decreased placental weight (392g vs 422g, p=0.09). MVM, in turn,
was significantly associated with PTD and LBW (p=0.002 and p<0.0001) and association with
SGA was borderline significant (p=0.09).
89
90   **Conclusion.**
91   ART initiation prior to pregnancy was associated with an increased risk of maternal vascular
92   malperfusion and decidual arteriopathy, suggestive of placental dysfunction. The
93   association between MVM with PTD and LBW suggests that a placenta-mediated
94   mechanism may link the putative association between ART and adverse birth outcomes.
95

Introduction
Antiretroviral therapy (ART) is now recognized as the standard of care for the management
of HIV-infected pregnant women, for the prevention of mother-to-child transmission
(MTCT) and improved maternal health and survival.[1,2] This has lead to a rapid rise in fetal
exposure to antiretrovirals and this *in-utero* exposure has been associated with increased
risk of adverse birth outcomes, including preterm delivery (PTD),[3–5] low birth weight (LBW)[6]
and small-for-gestational age (SGA) infants.[3,7]

HIV infection in pregnancy has been associated with an increased risk of adverse birth
ouctomes and this is thought to be through inflammatory-mediated disruption of placental
development and function.[8,9] Placental structure and function can affect the both maternal
health, as seen in eclampsia[10] and fetal health, with PTD and SGA.[8,11–13] Uncharacteristic
placental shapes and sizes may also indicate decreased placental efficiency, and maternal
supply-line deprivation.[14,15] Histologic chorioamnionitis reflects maternal and fetal
inflammatory responses to ascending infection,[16,17] and is a major cause of spontaneous
PTD.[18–20] Despite recognition of the importance of the placenta in adverse birth outcomes,
there is scant data on the impact of *in-utero* ART exposure on placental development and
pathology.

We set out to systematically examine the histopathology of placentas collected at delivery
from HIV-infected mothers receiving ART before or during pregnancy, to inform
understanding of the possible impact of ART initiation timing on placental pathology. We
hypothesized that initiating of ART during pregnancy would result in greater inflammatory
placental pathology compared to ART initiated before pregnancy.

Materials and Methods
We established a nested sub-study in the Prematurity Immunology in HIV-infected Mothers
and their infants Study (PIMS) cohort in Cape Town, South Africa[21]. PIMS was a prospective
cohort study investigating the association between ART use, and adverse birth outcomes, in
particular PTD, SGA and LBW.[21] Pregnant women seeking antenatal care (ANC) services at
the Gugulethu Midwife Obstetric Unit (MOU), were recruited between April 2015 and
October 2016, at ≤24 weeks gestation. Whole placentas were collected when available and
processed within 24 hours of delivery. This nested sub-study consisted of those who
initiated ART before pregnancy (stable group), and those who initiated ART at the first ANC
visit (initiating group). ART regimens consisted mainly of tenofovir (TDF)+ lamivudine
(3TC)/emtricitabine (FTC) + efavirenz (EFV).[21]

Ethical considerations
The PIMS study protocol, informed consent forms and all data collection tools were
approved by the University of Cape Town, Faculty of Health Sciences Human Research Ethics
Committee (UCT-HREC) project #739/2014 approved on 30th October 2014 and the

University of Southampton Faculty of Medicine Ethics Committee project # 12542 PIMS
approved on 24th November 2014. Written informed consent was obtained from all study
participants, including placenta collection for the nested cohort.

Data collection
At the first ANC visit for each woman, an ultrasound scan (USS) was used to guage
gestational age by a research sonographer using a standardized assessment protocol and
blinded to routine ANC assessments. Obstetric outcomes, including date of delivery and
birthweight, were obtained from clinical records. Maternal CD4 and viral load
measurements were obtained from hospital records at the time closest to the first ANC visit.
Body Mass Index (BMI) was based on weight and height measurements, and blood pressure
were measured at the first ANC visit (baseline) and during follow-up. Substance use,
including alcohol intake, smoking and/or drug use, was self-reported.

Placenta collection and processing
Whole placentas were collected at delivery when available and fixed in 10% buffered
formalin prior to histopathology examination. Placenta processing and histopathological
examination were performed in the Department of Pathology, Red Cross Memorial
Children's Hospital, Cape Town, South Africa. Specimens were examined, and samples from
the umbilical cord, membranes and placental disk obtained were scored following the
Amsterdam Placental Workshop Group Consensus Statement.[22] Briefly, four blocks were
prepared from each placenta, one block included a roll of the extraplacental membranes
and two cross sections of the umbilical cord, one from the placental insertion, and one close
to the fetal end. In addition, three blocks each contained a full-thickness section of the
placenta parenchyma, one from a visibly abnormal area if present and two sections from
macroscopically normal tissue including one from the cord insertion. The tissue sections
were 3-5μm thick and were cut and stained with hematoxylin and eosin for histological
examination. Macroscopic and microscopic features were combined to report cluster
diagnoses. For the sake of pathology scoring rigour, sections were also assesed in the
Department of Histopathology, Sheffield Children Hospital NHS Foundation Trust, Sheffield,
UK.

Variables of interest
Placenta pathology was based on placenta weight for gestational age, fetal-placental weight
ratio and cluster diagnoses. All placenta weights were reported as trimmed weights, after
removal of umbilical cords and membranes. Placenta weight percentiles by gestational age
and fetal-placenta ratios were categorized as small ($<10^{th}$), appropriate ($10 - 90^{th}$) and large
($>90^{th}$) for gestational age.[23] The cluster diagnoses for these specimens included, meconium
exposure based on the presence and amount of meconium-laden macrophages in the
placental membranes, with some cases showing features of prolonged exposure
characterized by meconium deep in the chorionic plate and umbilical cord; amnion

degeneration and chorion vascular muscle necrosis.[24] Histologic chorioamnionitis was
defined as the presence of acute inflammation in the placenta and specified with or without
a fetal inflammatory response.[25,26] Maternal vascular malperfusion (MVM) was defined
based on a constellation of findings including macroscopic placental hypoplasia reflected by
placental weight that is small for gestational age (<10th centile), presence of infarcts and/or
retroplacental haemorrhage; in addition to the presence of microscopic abnormalities of
villous development associated or not with placental infarcts and/or decidual
arteriopathy.[22,27] Chronic deciduitis was defined as abnormal infiltration of lymphocytes and
plasma cells in the decidua.[22,28] Decidual arteriopathy was defined as abnormal or
incomplete remodelling of decidual spiral arterioles resulting in fibrinoid necrotic
lesions.[22,29] Placenta disk dimensions were recorded as maximum linear dimension (*length*),
greatest dimension of the axis perpendicular to the *length* (*width*) and the thickness. Cord
insertion referred to site of insertion on the placenta in relation to the margin of the
placenta classified as central, off-centre and marginal based on the distance from the
margin.
193
Secondary outcomes included PTD, SGA and LBW. In analysis, gestation was based on the
number of completed weeks prior to delivery and PTD was defined as delivery at <37 weeks'
gestation.[30] Birthweight was categorized as low (LBW, <2500g), normal (NBW, 2500-4000g)
and high (HBW, >4000g).[31] Size for gestational age, based on gender-specific
INTERGROWTH-21st project standards, was defined as SGA for infants with birthweight <10th
percentile for gestational age, appropriate for gestational age (AGA) for those between 10 -
90th percentile and large for gestational age (LGA) for those >90th percentiles.[32]
201
Statistical analysis
Statistical analyses were performed using STATA version 12.0 (Stata Corporation, College
Station, Texas, USA) and R. Analyses focused on placenta pathology outcomes by ART
initiation timing before or during pregnancy. The impact of ART timing on the five placental
pathology clusters was summarized in an Alluvial plot generated using the ggalluvial
package in R.[33] Secondary analyses focused on birth outcomes (PTD, LBW and SGA) with
pathology cluster diagnosis as exposure. In bivariable analyses, proportions were compared
using chi-squared/Fishers exact test and rank-sum tests. The associations between baseline
characteristics and placenta pathology outcomes (small placental weight for GA, MVM and
chorioamnionitis) were assessed using binomial regression. Results were presented as risk
ratios (RR) with 95% confidence intervals (CI) generated using the forestplot package in R (R
package version 1.9).[34] For secondary analyses of birth outcomes, given the limited sample
size only bivariate analyses were conducted. Placenta weight and MVM abnormalities are
likely to originate in early gestation, and we thus sought to explore any associations
between timing of ART initiation and these placenta pathologies. To assess potential risk
factors for PTD (<37 weeks gestational age), size for gestational age (<10th percentile) and

LBW (<2500g), we compared differences between groups using the chi^2 test or Fisher's
exact test.
220
221
222
223   **Results**
224   We received 130 placentas that were of good quality using our described grading 1-3[35],
225   where 53 (40.8%) were from the stable group and 77 (59.2%) from initiating women.
226   Maternal and obstetric characteristics are summarised in Table 1.
227
Maternal characteristics
Women in the stable group were older (median 33 years, IQR 28-37) than initiating women
(median 28, IQR 25-32, p=0.003). Median gestational age at enrolment was 15 weeks (IQR
11-18), similar for the two ART groups (Table 1). Nearly all, 119 (91%), women were on a
fixed dose regimen of Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV) and only 3 (2%;
all in the stable group) were on a protease inhibitor (PI)-based regimen. Stable women had
significantly higher median CD4 T cell counts at enrolment (455 cells/ml, IQR 381 - 602) than
initiating women (369.5 cells/ml, IQR 251 - 534.5) (p=0.04). Most women had undetectable
viral load at the time closest to the first ANC visit. Most women (78.4%) were overweight or
obese and not significantly different by ART group. Initiating women were more likely to be
prehypertensive than stable women (28.6% vs 11.3%, p=0.03). Alcohol was the most used
substance, with 22% of women reporting alcohol use < 30 days prior to first ANC visit (Supp.
Table 1). There was no difference in smoking or recreational drug use between the two
groups.
242
Infant characteristics
Of the 130 live singleton births, 58 (44.6%) were female and 72 (55.3%) were male infants
(Table 2), with no difference in gender representation between the two groups. Overall,
median gestation at delivery was 39 weeks (IQR 38 - 40) and PTD incidence was low (6.9%)
with no difference according to timing of ART initiation. While median birthweight was also
similar between ART groups there were however differences observed in the incidence of
LBW (11.3% *vs* 6.5%) and HBW (1.9% *vs* 9.1%) deliveries between women in the stable and
initiating group respectively. Differences were also observed in size for gestational age,
where 12 (9.2%) infants were SGA, with 8 (15.1%) in the stable and 4 (5.2%) in the initiating
group.
253
Placental Pathology.
Table 3 shows placenta characteristics and pathology stratified by timing of ART initiation
and Figures 1A-D show representative images of some of the placenta clusters included in
our analysis: chorioamnionitis (Figure 1A), neutrophilic infiltrate involving the cord vein
representing a fetal response (Figure 1B) and decidual artery atherosis (Figure 1C). Median

placenta basal plate weight was 412g (IQR 350 - 480) overall, 393g in the stable and 422g in
the initiating group (p=0.09). Overall, 43 (33%) placentas were <10th percentile weight-for-
gestation, with no significant differences between ART groups; placental diameter, thickness
or cord insertion were also similar in each group as was the Fetal-Placental weight ratio.
Meconium exposure was identified in 22 (19.2%) cases, similar in both ART group.
Chorioamnionitis was present in 19 (14.6%) cases, with a higher percentage in initiating
women than in stable women, but not reaching statistical significance. MVM was
significantly higher in placentas from stable than initiating women (39.2% vs 19.5%; p=0.01)
as was decidual arteriopathy (11.3% vs 1.3%; p=0.02).

To discount selection bias due to collection of placentas from a sub-group of women, we
compared maternal characteristics in "no-placenta" versus "placenta" collection for each
ART group (Supp Table 2). Importantly, blood pressure was no different in the wider cohort
(n=421), irrespective of ART group, indicating that the observed MVM and decidual
arteriopathy in the smaller placenta stable group was not due to any bias in a pre- or
hypertensive state, which may have impacted upon our observations.

Figures 2A-C shows the relative risk of placenta pathology by ART group and maternal
characteristics. In unadjusted models, women who were overweight (p=0.007) and obese
(p<0.0001) were less likely to have small-for-gestational age placentas (Figure 2A). None of
the variables explored were associated with significant risk of chorioamionitis (Figure 2B).
The risk of MVM (Figure 2C) was twice as high (p=0.01) in stable women than in initiating
women. The impact of ART timing on the five placental pathology clusters is summarized in
the Alluvial plot in Figure 2D, emphasizing the occurrence of decidual arteriopathy and
MVM in women initiating ART pre-pregnancy. The association between placenta pathology
with PTD, SGA and LBW (Table 4) was significant for MVM (PTD: p=0.002; LBW: p<0.0001),
with a trend for SGA (p=0.09). In addition, SGA deliveries were more likely to present with
meconium exposure, an indicator of fetal distress (p=0.01).

Comment
Principal findings of the study
This is the first study to examine the association between timing of ART initiation in HIV-
infected women and placental pathology. Placentas from women who had initiated ART
before pregnancy, but not those initiating in pregnancy, showed substantially increased
maternal vascular malperfusion (MVM) and decidual arteriopathy. There was no evidence
for overt maternal or fetal inflammation in either ART group, contrary to our initial
hypothesis. MVM significantly associated with PTD and LBW and the association with
decidual arteriopathy with PTD was borderline significant. These findings suggest that
associations between ART and adverse birth outcomes may be placenta-mediated,
especially so for women initiating ART before pregnancy, where there is antiretroviral drug
exposure during placental implantation and development.

Results in comparison with previous studies

Results in comparison with previous studies
Previous studies of HIV-infected women initiating ART before or during pregnancy have
focused on quantifying risk of PTD,[3,6,36–40] SGA,[3,6,40,41] LBW,[6,37,38] stillbirth[42] and/or neontal
death[41]; virologic failure;[43] MTCT[44] maternal plasma angiogenic factors,[45] and maternal
virologic and immunologic responses.[46] This is the first study to investigate placenta
pathology in association with timing of ART initiation. Our women who initiated ART before
pregnancy were significantly older and multigravid and similar to a study in Botswana.[3] In
this cohort, women who initiated ART before pregnancy had higher median CD4 counts at
enrolment than women who initiated ART during pregnancy; the prognosis of patients with
HIV often correlates with levels of CD4 and as expected the CD4 counts of women who were
already on treatment were increased after ART initiation.[47] Although HIV-infected
individuals on ART have been shown to have a high prevalence of hypertension,[48] women
on stable ART in our study were less likely to be pre- or hypertensive than those initiating
during pregnancy.

Our high incidence of MVM was consistent with that found in a previous HIV-infected
pregnancy cohort.[49] We found MVM to be a key finding associating with PTD and LBW. All
cases of decidual arteriopathy also presented with MVM suggesting that prolonged ART was
associated with placental injury and poor perfusion. We speculate that MVM and decidual
arteriopathy may underlie the decreased placental weight due to poor placental perfusion
and deep placentation.

Clinical Implications
Women who initiated ART before pregnancy were substantially more likely to present with
MVM and decidual arteriopathy. MVM represents a pattern of placental injury which affects
the maternal vasculature and circulation and thus often associates with significantly
increased risk of adverse effects to the fetus.[22,27] We found MVM to be significantly
associated with decidual arteriopathy, indicating that placental insuffiency is a feature in
HIV-infected women on ART, regardless of when the regimen was initiated. We did not find
any associations between MVM and hypertensive disorders in our cohort, although
hypertensive disorders of pregnancy, including preeclampsia and chronic hypertension, are
the classical maternal clinical features associated with an increased risk of MVM.[50–52] Our
data shows that interventions aiming to mitigate adverse birth outcome associated with
ART should not ignore the placenta.

Research Implications
We show that exposure to ART could affect the maternal blood flow in the placenta
inducing pathology that is subsequently associated with adverse birth outcomes. The impact
of ART exposure on the placenta is under-explored and research is required to elucidate
potential mechansims. We speculate that exposure of ART before or during early pregnancy

results in systemic maternal inflammation that may disrupt vasculogenesis and
angiogenesis.[8] In our women, the underlying mechanism leading to this disruption may be
dysregulation of pro-angiogenic mediators including placental growth factor (PlGF), soluble
endoglin (sEng) and angiopoietin-1 (Ang-1). Although data is scarce, previous findings
demonstrate that maternal HIV infection and ART exposure is associated with an altered
pro-angiogenic state; including lower PlGF, higher sEng, decreased Ang-2 and increased
Ang-1.[9,53–55] We postulate that the higher incidence of MVM in women who initiate ART
before pregnancy was likely due to ART-associated shifts towards an anti-angiogenic state,
based on previous evidence linking ART with dysregulated angiogenesis and compromised
placental vascular development, especially when initiated in early pregnancy.[56] This may
account for the increased MVM in women intiating ART pre-conception; suggestive that ART
exposure could have detrimental effects on placental development characterized by altered
uterine and intervillous blood flow dynamics.
354
355 In addition to elucidating mechansims at the placental level, a maternal systemic predictor
356 of MVM needs to be developed. Circulating pro-angiogenic mediators like the placental
357 growth factor (PlGF), soluble endoglin (sEng) and angiopoietin-1 (Ang-1) that associate with
358 MVM and could be predictors of placental pathology.
359
Strengths and Limitations
The main strength of our study is the cohort design allowing us to compare two groups of
pregnant women receiving the same NNRTI-based ART regimen and enrolled early in
gestation, with data collected and samples investigated according to a strict protocol.
Additional strength lies in the ultrasound-based gestational age assessment, leading to
accurate PTD determination. Limitations include the non-random nature of the selection of
the nested-cohort, giving rise to potential differences in maternal characteristics between
ART groups. However, we doubt this as there was no significant difference in maternal
characteristics when we compared the placenta sub-group with the overall cohort where no
placentas were collected. Due to the limited sample size and number of cases, we restricted
our evaluation to bivariate analyses, although this should not substantially impact on our
placenta findings.
372
373 **Conclusions**
374 Women receiving ART prior to pregnancy was associated with an increased risk of maternal
375 vascular malperfusion and decidual arteriopathy, suggestive of placental dysfunction. The
376 association between MVM with PTD and LBW suggests that a placenta-mediated
377 mechanism may link the putative association between ART and adverse birth outcomes.
378

ACKNOWLEDGEMENTS
We thank all the study participants in this study; and all the members of the PIMS study. We also wish to thank Sue Ford, Colin Newell for data management and Michael Zulu for specimen processing.

Author contributions
Clive M Gray, Marie-Louise Newell, Thokozile R Malaba, Landon Myer: Conceptualization and design of the study
Thokozile R Malaba, Hlengiwe P Madlala: study conduct, data collection and specimen collection
Nadia M Ikumi: Laboratory and sample preparation
Komala Pillay, Marta Cohen: Histopathology scoring and interpretation
Nadia M Ikumi, Thokozile R Malaba: Statistical analysis
Nadia M Ikumi, Thokozile R Malaba, Clive Gray, Hlengiwe P Madlala, Marie-Louise Newell, Mushi Matjila, Dilly Anumba, Landon Myer: Writing the manuscript, review and editing

REFERENCES

397   1.   World Health Organization. *Programmatic Update Use of Antiretroviral Drugs for*
398   *Treating Pregnant Women and Preventing Hiv Infection in Infants Executive Summary.*
399   Vol 45.; 2012. doi:10.1162/LEON_r_00464
400   2.   Slogrove AL, Powis KM, Johnson LF, Stover J, Mahy M. Estimates of the global
401   population of children who are HIV-exposed and uninfected, 2000–18: a modelling
402   study. *Lancet Glob Heal*. 2020;8(1):e67-e75. doi:10.1016/S2214-109X(19)30448-6
403   3.   Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse
404   birth outcomes among HIV-infected women in Botswana. *J Infect Dis*.
405   2012;206(11):1695-1705. doi:10.1093/infdis/jis553
406   4.   Short C-ES, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating
407   antiretroviral therapy to prevent HIV mother-to-child transmission. *HIV Med*.
408   2014;15(4):233-238. doi:10.1111/hiv.12083
409   5.   Thorne C, Patel D, Newell M-L. Increased risk of adverse pregnancy outcomes in HIV-
410   infected women treated with highly active antiretroviral therapy in Europe. *AIDS*.
411   2004;18(17):2337-2339. doi:10.1097/00002030-200411190-00019
412   6.   Li N, Sando MM, Spiegelman D, et al. Antiretroviral Therapy in Relation to Birth
413   Outcomes among HIV-infected Women: A Cohort Study. *J Infect Dis*.
414   2016;213(7):1057-1064. doi:10.1093/infdis/jiv389
415   7.   Zash R, Souda S, Chen JY, et al. Reassuring Birth Outcomes With
416   Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child
417   Transmission of HIV in Botswana. *J Acquir Immune Defic Syndr*. 2016;71(4):428-436.
418   doi:10.1097/QAI.0000000000000847
419   8.   Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The Impact of Infection in
420   Pregnancy on Placental Vascular Development and Adverse Birth Outcomes. *Front*
421   *Microbiol*. 2019;10. doi:10.3389/fmicb.2019.01924
422   9.   Conroy AL, McDonald CR, Gamble JL, et al. Altered angiogenesis as a common
423   mechanism underlying preterm birth, small for gestational age, and stillbirth in
424   women living with HIV. *Am J Obstet Gynecol*. 2017;217(6):684.e1-684.e17.
425   doi:10.1016/j.ajog.2017.10.003
426   10.   Fisher SJ. Why is placentation abnormal in preeclampsia? *Am J Obstet Gynecol*.
427   2015;213(4):S115-S122. doi:10.1016/j.ajog.2015.08.042
428   11.   Romero R, Kusanovic JP, Chaiworapongsa T, Hassan SS. Placental bed disorders in
429   preterm labor, preterm PROM, spontaneous abortion and abruptio placentae. *Best*
430   *Pract Res Clin Obstet Gynaecol*. 2011;25(3):313-327.
431   doi:10.1016/j.bpobgyn.2011.02.006
432   12.   Doyle RM, Alber DG, Jones HE, et al. Term and preterm labour are associated with
433   distinct microbial community structures in placental membranes which are
434   independent of mode of delivery. *Placenta*. 2014;35(12):1099-1101.
435   doi:10.1016/j.placenta.2014.10.007
436   13.   Morgan T. Role of the Placenta in Preterm Birth: A Review. *Am J Perinatol*.
437   2016;33(03):258-266. doi:10.1055/s-0035-1570379
438   14.   Salafia CM, Yampolsky M, Misra DP, et al. Placental surface shape, function, and
439   effects of maternal and fetal vascular pathology. *Placenta*. 2010;31(11):958-962.
440   doi:10.1016/j.placenta.2010.09.005
15.   Freedman AA, Hogue CJ, Marsit CJ, et al. Associations Between the Features of Gross

Placental Morphology and Birthweight. *Pediatr Dev Pathol*. 2019;22(3):194-204.
doi:10.1177/1093526618789310

16.   Redline RW. Inflammatory response in acute chorioamnionitis. *Semin Fetal Neonatal*
Med. 2012;17(1):20-25. doi:10.1016/j.siny.2011.08.003

17.   Ategeka J, Wasswa R, Olwoch P, et al. The prevalence of histologic acute
chorioamnionitis among HIV infected pregnant women in Uganda and its association
with adverse birth outcomes. Robboy SJ, ed. *PLoS One*. 2019;14(4):e0215058.
doi:10.1371/journal.pone.0215058

18.   Galinsky R, Polglase GR, Hooper SB, Black MJ, Moss TJM. The Consequences of
Chorioamnionitis: Preterm Birth and Effects on Development. *J Pregnancy*.
2013;2013:1-11. doi:10.1155/2013/412831

19.   Prince AL, Ma J, Kannan PS, et al. The placental membrane microbiome is altered
among subjects with spontaneous preterm birth with and without chorioamnionitis.
Am J Obstet Gynecol. 2016;214(5):627.e1-627.e16. doi:10.1016/j.ajog.2016.01.193

20.   Wortham JM, Hansen NI, Schrag SJ, et al. Chorioamnionitis and Culture-Confirmed,
Early-Onset Neonatal Infections. *Pediatrics*. 2016;137(1):e20152323.
doi:10.1542/peds.2015-2323

21.   Malaba TR, Gray CM, Myer L, Newell M-L. Cohort Profile: Prematurity Immunology in
HIV-infected Mothers and their infants Study (PIMS). *medRixv*. Published online
2020:2020.03.18.20033654. doi:10.1101/2020.03.18.20033654

22.   Khong TY, Mooney EE, Ariel I, et al. Sampling and Definitions of Placental Lesions:
Amsterdam Placental Workshop Group Consensus Statement. *Arch Pathol Lab Med*.
2016;140(7):698-713. doi:10.5858/arpa.2015-0225-CC

23.   Kraus FT. *Placenta Pathology*. (American Registry of Pathology, ed.). American
Registry of Pathology; 2004.

24.   Kim B, Oh S, Kim J-S. Placental Lesions in Meconium Aspiration Syndrome. *J Pathol*
Transl Med. 2017;51(5):488-498. doi:10.4132/jptm.2017.07.20

25.   Kallapur S, Presicce P, Rueda C, Jobe A, Chougnet C. Fetal Immune Response to
Chorioamnionitis. *Semin Reprod Med*. 2014;32(01):056-067. doi:10.1055/s-0033-
1361823

26.   Kim CJ, Romero R, Chaemsaithong P, Chaiyasit N, Yoon BH, Kim YM. Acute
chorioamnionitis and funisitis: definition, pathologic features, and clinical
significance. *Am J Obstet Gynecol*. 2015;213(4):S29-S52.
doi:10.1016/j.ajog.2015.08.040

27.   Ernst LM. Maternal vascular malperfusion of the placental bed. *APMIS*.
2018;126(7):551-560. doi:10.1111/apm.12833

28.   Ziadie M. Chronic deciduitis. PathologyOutlines.com website. Accessed March 30,
2020. https://www.pathologyoutlines.com/topic/placentachronicdecid.html

29.   Heider A. Fetal Vascular Malperfusion. *Arch Pathol Lab Med*. 2017;141(11):1484-
1489. doi:10.5858/arpa.2017-0212-RA

30.   World Health Organization. Preterm Birth. Accessed March 30, 2019.
https://www.who.int/news-room/fact-sheets/detail/preterm-birth

31.   Ota E, Haruna M, Suzuki M, et al. Maternal body mass index and gestational weight
gain and their association with perinatal outcomes in Viet Nam. *Bull World Health*
Organ. 2011;89(2):127-136. doi:10.2471/BLT.10.077982

32.   Papageorghiou AT, Kennedy SH, Salomon LJ, et al. The INTERGROWTH-21 st fetal
growth standards: toward the global integration of pregnancy and pediatric care. *Am*

J Obstet Gynecol. 2018;218(2):S630-S640. doi:10.1016/j.ajog.2018.01.011

33.   Brunson JC. ggalluvial: Alluvial Plots in "ggplot2." Published online 2020.
https://cran.r-project.org/package=ggalluvial

34.   Gordon M, Lumley T. forestplot: Advanced Forest Plot Using "grid" Graphics.
Published online 2019.

35.   Malaba TR, Gray CM, Myer L, Newell M-L. Cohort Profile: Prematurity Immunology in
HIV-infected Mothers and their infants Study (PIMS). *medRxiv*. Published online
January 1, 2020:2020.03.18.20033654. doi:10.1101/2020.03.18.20033654

36.   Aniji CD, Towobola OA, Hoque ME, Mashamba TJ, Monokoane S. Impact of
antiretroviral therapy on pregnancy outcomes. *South Afr J HIV Med*. 2013;14(4):176.
doi:10.7196/sajhivmed.834

37.   Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome in women infected with
HIV-1 receiving combination antiretroviral therapy before versus after conception.
Sex Transm Infect. 2009;85(2):82-87. doi:10.1136/sti.2008.032300

38.   Chetty T, Thorne C, Coutsoudis A. Preterm delivery and small-for-gestation outcomes
in HIV-infected pregnant women on antiretroviral therapy in rural South Africa:
Results from a cohort study, 2010-2015. *PLoS One*. 2018;13(2):e0192805.
doi:10.1371/journal.pone.0192805

39.   Stoner MCD, Cole SR, Price J, Winston J, Stringer JSA. Timing of Initiation of
Antiretroviral Therapy and Risk of Preterm Birth in Studies of HIV-infected Pregnant
Women: The Role of Selection Bias. *Epidemiology*. 2018;29(2):224-229.
doi:10.1097/EDE.0000000000000772

40.   Malaba TR, Phillips T, Le Roux S, et al. Antiretroviral therapy use during pregnancy
and adverse birth outcomes in South African women. *Int J Epidemiol*.
2017;46(5):1678-1689. doi:10.1093/ije/dyx136

41.   Santosa WB, Staines-Urias E, Tshivuila-Matala COO, Norris SA, Hemelaar J. Perinatal
outcomes associated with maternal HIV and antiretroviral therapy in pregnancies
with accurate gestational age in South Africa. *AIDS*. 2019;33(10):1623-1633.
doi:10.1097/QAD.0000000000002222

42.   Msukwa MT, Keiser O, Jahn A, et al. Timing of combination antiretroviral therapy
(cART) initiation is not associated with stillbirth among HIV-infected pregnant women
in Malawi. *Trop Med Int Health*. 2019;24(6):727-735. doi:10.1111/tmi.13233

43.   Onoya D, Sineke T, Brennan AT, Long L, Fox MP. Timing of pregnancy, postpartum risk
of virologic failure and loss to follow-up among HIV-positive women. *AIDS*.
2017;31(11):1593-1602. doi:10.1097/QAD.0000000000001517

44.   Dinh T-H, Mushavi A, Shiraishi RW, et al. Impact of Timing of Antiretroviral Treatment
and Birth Weight on Mother-to-Child Human Immunodeficiency Virus Transmission:
Findings From an 18-Month Prospective Cohort of a Nationally Representative
Sample of Mother–Infant Pairs During the Transition Fro. *Clin Infect Dis*.
2018;66(4):576-585. doi:10.1093/cid/cix820

45.   Djeha A, Girard S, Trottier H, et al. No association between early antiretroviral
therapy during pregnancy and plasma levels of angiogenic factors: a cohort study.
BMC Pregnancy Childbirth. 2019;19(1):482. doi:10.1186/s12884-019-2600-4

46.   Melekhin V V, Shepherd BE, Stinnette SE, et al. Antiretroviral therapy initiation
before, during, or after pregnancy in HIV-1-infected women: maternal virologic,
immunologic, and clinical response. *PLoS One*. 2009;4(9):e6961.
doi:10.1371/journal.pone.0006961

47. Bishop JD, DeShields S, Cunningham T, Troy SB. CD4 Count Recovery After Initiation of
Antiretroviral Therapy in Patients Infected With Human Immunodeficiency Virus. *Am*
J Med Sci. 2016;352(3):239-244. doi:10.1016/j.amjms.2016.05.032
48. Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults. *Hypertension*.
2018;72(1):44-55. doi:10.1161/HYPERTENSIONAHA.118.10893
49. Kalk E, Schubert P, Bettinger JA, et al. Placental pathology in HIV infection at term: a
comparison with HIV-uninfected women. *Trop Med Int Health*. 2017;22(5):604-613.
doi:10.1111/tmi.12858
50. Kovo M, Bar J, Schreiber L, Shargorodsky M. The relationship between hypertensive
disorders in pregnancy and placental maternal and fetal vascular circulation. *J Am Soc*
Hypertens. 2017;11(11):724-729. doi:10.1016/j.jash.2017.09.001
51. Bustamante Helfrich B, Chilukuri N, He H, et al. Maternal vascular malperfusion of the
placental bed associated with hypertensive disorders in the Boston Birth Cohort.
Placenta. 2017;52:106-113. doi:10.1016/j.placenta.2017.02.016
52. Naderi S, Tsai SA, Khandelwal A. Hypertensive Disorders of Pregnancy. *Curr*
Atheroscler Rep. 2017;19(3):15. doi:10.1007/s11883-017-0648-z
53. Govender N, Naicker T, Moodley J. Maternal imbalance between pro-angiogenic and
anti-angiogenic factors in HIV-infected women with pre-eclampsia. *Cardiovasc J Afr*.
2013;24(5):174-179. doi:10.5830/CVJA-2013-029
54. Graham SM, Rajwans N, Jaoko W, et al. Endothelial activation biomarkers increase
after HIV-1 acquisition. *AIDS*. 2013;27(11):1803-1813.
doi:10.1097/QAD.0b013e328360e9fb
55. Graham SM, Rajwans N, Tapia KA, et al. A prospective study of endothelial activation
biomarkers, including plasma angiopoietin-1 and angiopoietin-2, in Kenyan women
initiating antiretroviral therapy. *BMC Infect Dis*. 2013;13(1):263. doi:10.1186/1471-
2334-13-263
56. Mohammadi H, Papp E, Cahill L, et al. HIV antiretroviral exposure in pregnancy
induces detrimental placenta vascular changes that are rescued by progesterone
supplementation. *Sci Rep*. 2018;8(1):6552. doi:10.1038/s41598-018-24680-w
565
566

567   **Table 1: Maternal and obstetric characteristics of the pregnant women at enrolment.**

	Total N=130	[1]ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	p-Value
Age, years				*0.003*
≤24	24 (18.5)	5 (9.4)	19 (24.7)	
25-29	36 (27.7)	10 (18.9)	26 (33.8)	
≥30	70 (53.8)	38 (71.7)	32 (41.5)	
Median (IQR)	31 (26 - 35)	33(28 - 37)	28 (25 - 32)	
Median Gestation at Enrolment	15 (11-18)	14 (11-18)	15 (11-18)	0.4
Gravidity				0.1
1	14 (10.8)	4 (7.5)	10 (13.0)	
2	50 (38.5)	16 (30.2)	34 (44.2)	
≥3	66 (50.8)	33 (62.3)	33 (42.9)	
[2]Previous Preterm				1.0
Yes	7 (5.4)	4 (7.5)	3 (3.9)	
No	61 (46.9)	30 (56.6)	31 (40.3)	
ART regimen				0.2
TDF-3TC-EFV	119 (91.5)	47 (88.7)	72 (93.5)	
AZT-3TC-NVP	2 (1.5)	1 (1.9)	1 (1.9)	
AZT-XTC-EFV	6 (4.6)	2 (3.8)	4 (5.2)	
PI-based regimen	3 (2.3)	3 (5.7)	0 (0)	
[3]CD4 cell count, cells/ml				*0.04*
≤ 200	9 (6.9)	1 (1.9)	8 (10.4)	
201-350	32 (24.6)	8 (15.1)	24 (31.2)	
351-500	29 (22.3)	14 (26.4)	15 (19.5)	
>500	41 (31.5)	20 (37.7)	21 (27.3)	
[3]Viral load, copies/ml				0.1
<400	84 (64.6)	45 (84.9)	39 (50.6)	
401-1000	2 (1.5)	0 (0)	2 (2.6)	
>1000	7 (5.4)	2 (3.8)	5 (6.5)	
[4]Body Mass Index, kg/m^2				0.5
Normal (18.5-24.9)	27 (20.7)	12 (22.6)	15 (19.5)	
Overweight (25.0-29.9)	41 (31.5)	18 (34.0)	23 (29.9)	
Obese (>30.0)	61 (46.9)	22 (41.5)	39 (50.6)	
Blood Pressure, Enrolment (mmHG)				*0.03*
Normal (Sys <120 and Dia <80)	99 (76.1)	46 (86.8)	53 (68.8)	
Prehypertensive (Sys 120-139 or Dia 80-89)	28 (21.5)	6 (11.3)	22 (28.6)	
Hypertensive (Sys >140 or Dia >90)	3 (2.3)	1 (1.9)	2 (2.6)	

568
569   [1]Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test
570   depending on the distribution for numerical data and the chi^2 test or Fisher's exact test for categorical data.
571   [2]Among women with a previous pregnancy
572   [3]CD4 and viral load results abstracted from routine records and are the nearest in time to the first ANC visit.
573   [4]At enrolment or first ANC
574

575 **Table 2: Infant characteristics**

	Total N=130	ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	p-Value
Infant Characteristics				
Sex				0.6
Female	58 (44.6)	25 (47.2)	33 (42.9)	
Male	72 (55.4)	28 (52.8)	44 (57.1)	
Median Delivery Gestation (completed weeks)	39 (38 - 40)	39 (38 - 39)	39 (38 - 40)	0.1
Birthweight, grams				0.2
Low birthweight (<2500g)	11 (8.5)	6 (11.3)	5 (6.5)	
Normal (2500 - 4000g)	111 (85.4)	46 (86.8)	65 (84.4)	
High (>4000g)	8 (6.1)	1 (1.9)	7 (9.1)	
Median (IQR)	3180 (2880 - 3540)	3140 (2690 - 3360)	3240 (2940 - 3580)	
Preterm (<37 weeks Gestational Age)				1.0
Yes	9 (6.9)	4 (7.5)	5 (6.5)	
No	121 (93.1)	49 (92.5)	72 (93.5)	
Size for Gestational Age, <10th centile				0.07
Yes	12 (9.2)	8 (15.1)	4 (5.2)	
No	118 (90.8)	45 (84.9)	73 (94.8)	
Mode of Delivery				0.2
Vaginal Delivery	97 (74.6)	42 (79.2)	55 (71.4)	
Elective Caesarean	24 (18.5)	4 (7.6)	4 (5.2)	
Emergency Caesarean	8 (6.1)	6 (11.3)	18 (23.4)	
Missing	*1 (0.8)*	*1 (1.9)*	*0 (0)*	

577 [1]Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

578 depending on the distribution for numerical data and the chi^2 test or Fisher's exact test for categorical data.

580   **Table 3: Placental characteristics and pathology at delivery among women initiating ART**

581   **before or during pregnancy.**

	Total N=130	[1]ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	P-value
Placental basal plate weight (g), median (IQR)	412 (346 - 480)	392 (346 − 440)	422 (344 − 490)	0.09
Placental weight (g)				1.0
Small (<10th percentile)	43 (33.1)	17 (32.1)	26 (33.8)	
Appropriate (10 - 90th percentile)	85 (65.4)	35 (66.0)	50 (64.9)	
Large (>90th percentile)	1 (0.8)	0 (0)	1 (1.3)	
Fetal-Placenta weight ratio				0.9
Small (<10th percentile)	3 (2.3)	1 (1.9)	2 (2.6)	
Appropriate (10 - 90th percentile)	81 (62.3)	32 (60.4)	49 (63.6)	
Large (>90th percentile)	45 (34.6)	19 (35.8)	26 (33.8)	
Placenta greatest diameter (mm), median (IQR)	170 (160 − 180)	175 (161 - 189)	170 (160 - 180)	0.1
Placenta thickness (mm), median (IQR)	17.5 (10 - 25)	15 (10 - 22)	20 (10 - 25)	0.4
Cord insertion				0.2
Central	21 (16.1)	7 (13.2)	14 (18.2)	
Off centre	91 (70.0)	35 (66.0)	56 (72.7)	
Marginal	17 (13.1)	10 (18.9)	7 (9.1)	
Meconium exposure				0.9
+	25 (19.2)	10 (18.9)	15 (19.5)	
-	105 (80.8)	43 (81.1)	62 (80.5)	
Chorioamnionitis				
Maternal Inflammatory Response				0.8
+	19 (14.6)	7 (13.2)	12 (15.6)	
-	111 (85.4)	46 (86.3)	65 (84.4)	
Fetal Inflammatory Response				0.1
+	20 (15.4)	5 (9.4)	15 (19.5)	
-	110 (84.6)	48 (90.6)	62 (80.5)	
Chronic Deciduitis				0.8
+	14 (10.8)	5 (9.4)	9 (11.7)	
-	116 (89.2)	48 (90.6)	68 (88.3)	
Decidual arteriopathy				***0.02***
+	7 (5.4)	6 (11.3)	1 (1.3)	
-	123 (94.6)	47 (88.7)	76 (98.7)	
Maternal Vascular Malperfusion (MVM)				***0.01***
+	36 (27.7)	21 (39.6)	15 (19.5)	
-	94 (72.3)	32 (60.4)	62 (80.5)	

582   [1]Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

583   depending on the distribution for numerical data and the chi[2] test or Fisher's exact test for categorical data.

585 **Table 4: Relationship between placenta pathology and preterm delivery, size for gestational age and low birthweight.**

	Total N=551	No Placenta N=421	Placenta N=130	P	No Placenta ART Initiation before pregnancy N=208	Placenta ART Initiation before pregnancy N=53	p	No Placenta ART Initiation during pregnancy N=213	Placenta ART Initiation during pregnancy N=77	p
Age, years				0.8			0.8			0.9
≤24	92 (16.7)	68 (16.2)	24 (18.5)		20 (9.6)	5 (9.4)		48 (22.5)	19 (24.7)	
25-29	156 (28.3)	120 (28.5)	36 (27.7)		48 (23.1)	10 (18.9)		72 (33.8)	26 (33.8)	
≥30	303 (55.0)	233 (55.3)	70 (53.8)		140 (67.3)	38 (71.7)		93 (43.7)	32 (41.5)	
Median (IQR)	30 (26-34)	30 (26-34)	31 (26-35)		32 (28-35)	33 (28-37)		29 (25-32)	28 (25-32)	
Median Gestation at Enrolment	14 (10-18)	13 (10-17)	14 (11-18)	0.04	13 (9-16)	13 (10-18)		14 (10-18)	15 (11-18)	
Gravidity				0.14			0.6			0.1
1	89 (16.1)	75 (17.8)	14 (10.8)		25 (12.0)	4 (7.5)		50 (23.5)	10 (13.0)	
2	189 (34.3)	139 (33.0)	50 (38.5)		63 (30.3)	16 (30.2)		76 (35.7)	34 (44.2)	
≥3	273 (49.6)	207 (49.2)	66 (50.8)		120 (57.7)	33 (62.3)		87 (40.8)	33 (42.9)	
ART regimen				0.1			0.7			0.06
TDF-3TC-EFV	499 (90.6)	380 (90.3)	119 (91.5)		173 (83.2)	47 (88.7)		207 (97.3)	72 (93.5)	
TDF-3TC-NVP	4 (0.7)	4 (0.9)	0 (0)		2 (0.9)	0 (0)		2 (0.9)	0 (0)	
AZT-3TC-NVP	10 (1.8)	8 (1.9)	2 (1.6)		8 (3.9)	1 (1.9)		0 (0)	1 (1.3)	
AZT-XTC-EFV	13 (2.4)	7 (1.7)	6 (4.6)		5 (2.4)	2 (3.8)		2 (0.9)	4 (5.2)	
PI-based regimen	25 (4.5)	22 (5.2)	3 (2.3)		20 (9.6)	3 (5.7)		2 (0.9)	0 (0)	
[1]Body Mass Index, kg/m^2				0.4			0.4			0.5
Normal (18.5-24.9)	115 (20.9)	88 (21.1)	27 (20.9)		38 (18.4)	12 (22.6)		50 (23.8)	15 (19.5)	
Overweight (25.0-29.9)	149 (27.0)	108 (25.9)	41 (31.8)		58 (28.0)	18 (34.0)		50 (23.8)	23 (29.9)	
Obese (>30.0)	282 (51.2)	221 (53.0)	61 (47.3)		111 (53.6)	22 (41.5)		110 (52.4)	39 (50.6)	
Blood Pressure, Enrolment (mmHG)				0.4			0.2			0.4
Normal (Sys <120 and Dia <80)	405 (73.5)	306 (72.7)	99 (76.2)		156 (75.0)	46 (86.8)		150 (70.4)	53 (68.8)	
Prehypertensive (Sys 120-139 or Dia 80-89)	123 (22.3)	95 (22.6)	28 (21.5)		45 (21.6)	6 (11.3)		50 (23.5)	22 (28.6)	
Hypertensive (Sys >140 or Dia >90)	23 (4.2)	20 (4.7)	3 (2.3)		7 (3.4)	1 (1.9)		13 (6.1)	2 (2.6)	

587 [1]To assess potential risk factors for preterm delivery (<37 weeks gestational age), size for gestational age (<10th percentile) and low birth weight (<2500g), we compared

588 differences between groups using the chi^2 test or Fisher's exact test.

589 **Supplementary Table 1: Substance use among study participants.**

	Total N=130	ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	p-Value
Substance Use†				
Alcohol				0.2
Yes	22 (16.9)	6 (11.3)	16 (20.8)	
No	105 (80.8)	45 (84.9)	60 (77.9)	
Missing	*3 (2.3)*	*2 (3.8)*	*1 (1.3)*	
Smoking				0.1
Yes	7 (5.4)	5 (9.4)	2 (2.6)	
No	121 (93.1)	46 (86.8)	75 (97.4)	
Missing	*2 (1.5)*	*2 (3.8)*	*0 (0)*	
Drugs				0.5
Yes	2 (1.5)	0 (0)	2 (2.6)	
No	126 (96.9)	51 (96.2)	75 (97.4)	
Missing	*2 (1.5)*	*2 (3.8)*	*0 (0)*	

590 †Substance use is self-reported over the last 30 days

591 [1]Differences between the two groups were assessed using a two-sample t-test or Wilcoxon rank-sum test

592 depending on the distribution for numerical data and the chi^2 test or Fisher's exact test for categorical data.

594 **Supplementary Table 2: Maternal and obstetric characteristics of pregnant women at enrolment: comparing no placenta vs placenta**

595 **collection.**

	Total	No Placenta	Placenta	p-value	No Placenta N=421			Placenta N=130		
	N=551	N=421	N=130		ART Initiation before pregnancy N=208	ART Initiation during pregnancy N=213	p-value	ART Initiation before pregnancy N=53	ART Initiation during pregnancy N=77	p-value
Age, years				0.83			<0.001			0.003
≤24	92 (16.7)	68 (16.2)	24 (18.5)		20 (9.6)	48 (22.5)		5 (9.4)	19 (24.7)	
25-29	156 (28.3)	120 (28.5)	36 (27.7)		48 (23.1)	72 (33.8)		10 (18.9)	26 (33.8)	
≥30	303 (55.0)	233 (55.3)	70 (53.8)		140 (67.3)	93 (43.7)		38 (71.7)	32 (41.5)	
Median (IQR)	30 (26-34)	30 (26-34)	31 (26-35)		32 (28-35)	29 (25-32)		33 (28 - 37)	28 (25 - 32)	
Median Gestation at Enrolment	14 (10-18)	13 (10-17)	14 (11-18)	0.04	14 (10-18)	13 (9-16)	0.02	14 (11-18)	15 (11-18)	0.4
Gravidity				0.14			0.001			0.1
1	89 (16.1)	75 (17.8)	14 (10.8)		50 (23.5)	25 (12.0)		4 (7.5)	10 (13.0)	
2	189 (34.3)	139 (33.0)	50 (38.5)		76 (35.7)	63 (30.3)		16 (30.2)	34 (44.2)	
≥3	273 (49.6)	207 (49.2)	66 (50.8)		87 (40.8)	120 (57.7)		33 (62.3)	33 (42.9)	
ART regimen				0.1			<0.001			0.2
TDF-3TC-EFV	499 (90.6)	380 (90.3)	119 (91.5)		173 (83.2)	207 (97.2)		47 (88.7)	72 (93.5)	
TDF-3TC-NVP	4 (0.7)	4 (0.9)	0 (0)		2 (0.9)	2 (0.9)		0 (0)	0 (0)	
AZT-3TC-NVP	10 (1.8)	8 (1.9)	2 (1.6)		8 (3.9)	0 (0)		1 (1.9)	1 (1.9)	
AZT-XTC-EFV	13 (2.4)	7 (1.7)	6 (4.6)		5 (2.4)	2 (0.9)		2 (3.8)	4 (5.2)	
PI-based regimen	25 (4.5)	22 (5.2)	3 (2.3)		20 (9.6)	2 (0.9)		3 (5.7)	0 (0)	
[1]Body Mass Index, kg/m^2				0.4			0.3			0.5
Normal (18.5-24.9)	115 (20.9)	88 (21.1)	27 (20.9)		38 (18.4)	50 (23.8)		12 (22.6)	15 (19.5)	
Overweight (25.0-29.9)	149 (27.0)	108 (25.9)	41 (31.8)		58 (28.0)	50 (23.8)		18 (34.0)	23 (29.9)	
Obese (>30.0)	282 (51.2)	221 (53.0)	61 (47.3)		111 (53.6)	110 (52.4)		22 (41.5)	39 (50.6)	
Blood Pressure, Enrolment (mmHG)				0.4			0.3			0.03
Normal (Sys <120 and Dia <80)	405 (73.5)	306 (72.7)	99 (76.2)		156 (75.0)	150 (70.4)		46 (86.8)	53 (68.8)	
Prehypertensive (Sys 120-139 or Dia 80-89)	123 (22.3)	95 (22.6)	28 (21.5)		45 (21.6)	50 (23.5)		6 (11.3)	22 (28.6)	
Hypertensive (Sys >140 or Dia >90)	23 (4.2)	20 (4.7)	3 (2.3)		7 (3.4)	13 (6.1)		1 (1.9)	2 (2.6)	

596
597 [1]At enrolment or first ANC

FIGURES

Figure 1

Figure 1A: Digital scan of a representative Haematoxylin and Eosin (H&E) stained section showing chorioamnionitis of the membranes (maternal response).

Figure 1B: Digital scan of a representative H&E stained section showing a neutrophilic infiltrate involving the cord vein wall extending into Wharton's jelly of the cord (fetal response).

Figure 1C: Digital scans of representative H&E stained sections of the basal plate showing an infarct. Inset 1 shows a magnified image of the infarct and Inset 2 shows a magnified foam cell (denoted by the arrow) within the decidual artery demonstrating atherosis.

Figure 2

Small Placenta size (<10th percentile)

Outcome: Small Placenta*	N (%)		Risk Ratio (95% CI)	p-Value
ART status				
Initiating	26(60.5)			
Stable	17(39.5)		1(0.59 - 1.60)	0.97
Maternal age (years)				
<=24	9(20.9)			
25-29	11(25.6)		0.81(0.4 - 1.66)	0.57
>=30	23(53.5)		0.89(0.48 - 1.64)	0.71
Maternal BMI, enrolment				
Normal	17(39.5)			
Overweight	12(27.9)		0.46(0.27 - 0.81)	0.007
Obese	14(32.6)		0.37(0.21 - 0.64)	0.001
Booking Blood Pressure				
Normal	36(83.7)			
Prehypertensive/Hypertensive	7(16.3)		0.61(0.3 - 1.24)	0.17
Any substance use				
No substance use	35(81.4)			
Substance use	8(18.6)		0.86(0.45 - 1.64)	0.65

Figure 2A: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting with a small placenta (<10th percentile for gestational age).

Figure 2

Figure 2B: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting histologic chorioamnionitis.

Figure 2

Figure 2C: Forest plot depicting the relative risk with the 95% confidence intervals of HIV infected women presenting with placental maternal vascular malperfusion.

Figure 2

Figure 2D: Alluvial plot depicting the impact of ART timing on the five placental pathology clusters among women initiating treatment before pregnancy (*Initiating*) or during pregnancy (*stable*). The plot depicts frequencies from a subset of women with abnormal placenta pathology only. These include DA (Decidual Arteriopathy), CA (Chorioamnionitis depicting FIR Fetal Inflammatory Response; MIR, Maternal Inflammatory Response), CD (Chronic Deciduitis), MVM (Maternal Vascular Malperfusion) and Meconium (Meconium Exposure) and the placenta size i.e. <10th percentile for gestational age (small) and > 10th percentile for gestational age (Normal) among women initiating treatment before pregnancy (*Initiating*) or during pregnancy (*stable*).